secwatch / observer
8-K filed April 29, 2026, 7:59 PM ET ticker MPLT CIK 0001770069
leadership confidence high sentiment neutral materiality 0.40

Two MapLight directors not standing for reelection; Babler and Cox nominated

MapLight Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Martin Babler

Class I Director
MPLT · MapLight Therapeutics, Inc.
Effective
2026-06-23
Filed
April 29, 2026, 7:59 PM ET
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
Departed

Jim Trenkle

Director
MPLT · MapLight Therapeutics, Inc.
Effective
2026-06-23
Successor
Martin Babler and Troy Cox
Filed
April 29, 2026, 7:59 PM ET
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
Appointed

Troy Cox

Class I Director
MPLT · MapLight Therapeutics, Inc.
Effective
2026-06-23
Filed
April 29, 2026, 7:59 PM ET
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
Departed

Robert Malenka

Director
MPLT · MapLight Therapeutics, Inc.
Effective
2026-06-23
Successor
Martin Babler and Troy Cox
Filed
April 29, 2026, 7:59 PM ET
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Babler was appointed as Class I Director at MapLight Therapeutics, Inc..

Action
nominated
Role
Class I Director
Exact text from the filing
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jim Trenkle departed as Director at MapLight Therapeutics, Inc..

Action
not stand for reelection
Role
Director
Exact text from the filing
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Troy Cox was appointed as Class I Director at MapLight Therapeutics, Inc..

Action
nominated
Role
Class I Director
Exact text from the filing
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Malenka departed as Director at MapLight Therapeutics, Inc..

Action
not stand for reelection
Role
Director
Exact text from the filing
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
View on SEC.gov

MapLight Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-191566
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.